These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 28668883

  • 1. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
    Nishi K, Luo H, Ishikura S, Doi K, Iwaihara Y, Wills L, Baillie GS, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2017 Jul; 37(7):3833-3839. PubMed ID: 28668883
    [Abstract] [Full Text] [Related]

  • 2. Growth Suppression of Human Colorectal Cancer Cells with Mutated KRAS by 3-Deaza-cytarabine in 3D Floating Culture.
    Luo H, Nishi K, Ishikura S, Swain A, Morishige N, Yazaki R, Ohshima T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2018 Jul; 38(7):4247-4256. PubMed ID: 29970558
    [Abstract] [Full Text] [Related]

  • 3. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
    Tsunoda T, Ishikura S, Doi K, Iwaihara Y, Hidesima H, Luo H, Hirose Y, Shirasawa S.
    Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
    [Abstract] [Full Text] [Related]

  • 4. Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture.
    Tsunoda T, Ishikura S, Doi K, Matsuzaki H, Iwaihara Y, Shirasawa S.
    Anticancer Res; 2014 Aug; 34(8):4551-5. PubMed ID: 25075098
    [Abstract] [Full Text] [Related]

  • 5. Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.
    Hashimoto S, Nagai M, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2021 Aug; 41(8):4061-4070. PubMed ID: 34281875
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model.
    Tsunoda T, Ota T, Fujimoto T, Doi K, Tanaka Y, Yoshida Y, Ogawa M, Matsuzaki H, Hamabashiri M, Tyson DR, Kuroki M, Miyamoto S, Shirasawa S.
    Mol Cancer; 2012 Jul 25; 11():46. PubMed ID: 22830422
    [Abstract] [Full Text] [Related]

  • 7. MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS.
    Nishi K, Tsunoda T, Uchida Y, Sueta T, Sawatsubashi M, Yamano T, Hashiguchi Y, Swain A, Shirasawa S, Sakata T.
    Anticancer Res; 2020 Aug 25; 40(8):4687-4694. PubMed ID: 32727793
    [Abstract] [Full Text] [Related]

  • 8. Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner.
    Yoshida K, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2022 Aug 25; 42(8):3993-4001. PubMed ID: 35896235
    [Abstract] [Full Text] [Related]

  • 9. A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.
    Okamoto H, Matsukawa T, Doi S, Tsunoda T, Sawata Y, Naemura M, Ohnuki K, Shirasawa S, Kotake Y.
    Mol Cell Biochem; 2018 May 25; 442(1-2):39-45. PubMed ID: 28936721
    [Abstract] [Full Text] [Related]

  • 10. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC, Qian Y, Li X, Xu J, Kang W, Tong JH, To KF, Jin Y, Li W, Chen H, Go MY, Wu JL, Cheng KW, Ng SS, Sung JJ, Cai Z, Yu J.
    Gastroenterology; 2016 Nov 25; 151(5):945-960.e6. PubMed ID: 27451147
    [Abstract] [Full Text] [Related]

  • 11. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM.
    Ann Surg Oncol; 2015 Dec 25; 22(13):4158-65. PubMed ID: 26077912
    [Abstract] [Full Text] [Related]

  • 12. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model.
    Yoshida Y, Tsunoda T, Doi K, Fujimoto T, Tanaka Y, Ota T, Ogawa M, Matsuzaki H, Kuroki M, Iwasaki A, Shirasawa S.
    Anticancer Res; 2012 Jun 25; 32(6):2301-8. PubMed ID: 22641666
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation.
    Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, Shirasawa S, Tsunoda T, Ueffing M, Xie J, Xin J, Wang X, Proud CG, Boldt K, Al-Khalili Szigyarto C, Kolch W, Lynn DJ.
    Br J Cancer; 2019 Jul 25; 121(1):37-50. PubMed ID: 31133691
    [Abstract] [Full Text] [Related]

  • 14. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 15. Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion.
    Nishi K, Ishikura S, Umebayashi M, Morisaki T, Inozume T, Kinugasa T, Aoki M, Nimura S, Swain A, Yoshida Y, Hasegawa S, Nabeshima K, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2020 Aug 20; 40(8):4663-4674. PubMed ID: 32727790
    [Abstract] [Full Text] [Related]

  • 16. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P, Gallardo A, Di Nicolantonio F, Pavón MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vázquez E, Bardelli A, Céspedes MV, Mangues R.
    FASEB J; 2015 Feb 20; 29(2):464-76. PubMed ID: 25359494
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory Effect of Pyra-Metho-Carnil on Cancer Spheroid Growth Through Decrease in Glycolysis-associated Molecules.
    Yoshida K, Nishi K, Ishikura S, Matsumoto T, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2023 Aug 20; 43(8):3717-3726. PubMed ID: 37500165
    [Abstract] [Full Text] [Related]

  • 18. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X, Zou F, Hu Z, Du G, Yu P, Wang W, Wang H, Ye L, Tian J.
    Toxicol Appl Pharmacol; 2020 Jul 01; 398():115019. PubMed ID: 32335126
    [Abstract] [Full Text] [Related]

  • 19. Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.
    Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Kuroki M, Sasazuki T, Shirasawa S.
    Anticancer Res; 2011 Jul 01; 31(7):2453-9. PubMed ID: 21873159
    [Abstract] [Full Text] [Related]

  • 20. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
    Sarkhosh-Inanlou R, Imani M, Sam MR.
    Biomed Pharmacother; 2020 Dec 01; 132():110807. PubMed ID: 33068939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.